Eledon Pharmaceuticals (Nasdaq: ELDN) Reports Fourth Quarter and Full Year 2025 Results

Strong Clinical Progress and Multiple Regulatory Milestones Set the Stage for 2026

IRVINE, Calif., March 19, 2026 — Eledon Pharmaceuticals announced its operating and financial results for the fourth quarter and full year 2025, with several significant updates that could materially impact shareholders. Below is a detailed breakdown of key developments, milestones, and financials that investors need to know.

Key Highlights for Investors

• Clinical Progress: Over 100 patients have now been treated with Eledon’s lead candidate, tegoprubart, an anti-CD40L antibody, across various transplantation programs. This growing patient data set supports the company’s strategy to position tegoprubart as a potential next-generation immunosuppressive therapy.
• Orphan Drug Designations: Tegoprubart received Orphan Drug designation from the FDA for the prevention of allograft rejection in liver transplantation. It previously received this designation for pancreatic islet cell transplantation and for the treatment of ALS. This regulatory progress is a critical value driver and de-risks future development.
• Positive Clinical Data:
  • Kidney Transplantation: 24-month follow-up data from the Phase 1b long-term extension trial (8 patients) showed continued favorable safety and tolerability. Notably, there were no biopsy-proven acute rejection episodes, graft loss, death, new-onset diabetes, or de novo donor-specific antibody formation. Mean eGFR improved from 67.0 to 74.2 mL/min/1.73m², indicating better kidney function over time.
  • Islet Cell Transplantation (Type 1 Diabetes): In an investigator-initiated study at University of Chicago Medicine, 12 patients have received tegoprubart. All 10 patients more than four weeks post-transplant achieved 100% insulin independence with a mean HbA1c of 5.35%. There were no rejection episodes, no de novo donor-specific HLA antibodies, and no evidence of nephrotoxicity, hypertension, or neurotoxicity — common side effects with standard immunosuppression.

Upcoming Potential Price-Moving Milestones

• Regulatory guidance from the FDA on the pivotal Phase 3 trial design for kidney transplantation, with trial initiation targeted post-alignment.
• Long-term data readouts from ongoing Phase 1 and 2 studies (BESTOW) in kidney transplantation.
• FDA regulatory guidance on paths to market for tegoprubart in islet cell transplantation and xenotransplantation.
• Initiation of new investigator-led studies in islet cell transplantation for patients with renal dysfunction, de novo liver transplant recipients, and for kidney transplant tolerance induction.

Financial Results (Year Ended December 31, 2025)

• Research & Development (R&D) Expenses: \$66.3 million (including \$4.2 million non-cash stock-based compensation), up from \$52.0 million in 2024. The increase reflects expanded clinical activity, manufacturing scale-up, and increased personnel costs.
• General & Administrative Expenses: \$17.0 million (including \$6.2 million non-cash stock-based compensation), down from \$18.6 million in 2024 due to lower stock-based compensation, offset by higher professional services and personnel costs.
• Net Loss: \$45.6 million, or \$0.52 per share (basic), compared to a net loss of \$36.2 million, or \$0.66 per share, in 2024. The 2025 result includes a non-cash gain of \$33.4 million from warrant liability valuation changes (2024: \$30.9 million gain). Excluding these non-cash items, the net loss would have been \$79.1 million (2024: \$67.1 million).
• Cash Position: Eledon ended the year with \$22.8 million in cash and cash equivalents, and \$110.5 million in short-term investments, for total current assets of \$135.7 million. This provides a significant operational runway into 2026.
• Shares Outstanding: 75,430,033 common shares issued and outstanding as of December 31, 2025 (up from 59,789,275 in 2024), reflecting capital raising activity.

What Shareholders Should Watch

• Regulatory and Clinical Catalysts: Feedback from the FDA and initiation of pivotal Phase 3 studies could drive significant share price movement. Orphan Drug designations enhance the company’s market exclusivity and potential for priority review or accelerated approval.
• Clinical Data Readouts: Positive long-term safety and efficacy data in kidney and islet transplantation underpin the investment thesis; however, further confirmation in larger trials is needed for commercialization.
• Financial Position: While Eledon has a strong cash balance, its cash burn is substantial, and future financing may be required to complete late-stage studies and support commercialization, potentially leading to dilution.
• Competitive and Regulatory Risks: The company faces risks common to clinical-stage biotechs, including regulatory setbacks, clinical trial delays, and the need to demonstrate superiority or non-inferiority to established immunosuppressive regimens.

Conclusion

Eledon Pharmaceuticals has delivered a strong set of clinical and regulatory milestones in 2025, particularly with tegoprubart’s progress in transplantation and its FDA Orphan Drug designation for liver transplantation. The upcoming year presents multiple catalysts that could influence the company’s valuation. Investors should closely monitor clinical trial progress, regulatory feedback, and the company’s cash runway and financing strategy.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with professional financial advisors before making investment decisions. The company’s forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those discussed herein.

View Eledon Pharmaceuticals, Inc. Historical chart here